Intratumoral injection of TLR9 agonists enhances the efficacy of anti–PD-1 ICB therapy in mouse models of pancreatic cancer (15) and head and neck squamous cell carcinoma (16). Here, TLR9 is linked to head and neck squamous cell carcinoma.